Andrew Jones

Andrew Jones

Auto-generated profile, based on publicly available information

Andrew Jones

Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Nature
Verified
Journal Article
Closed access
PDF file
RYRachel Yamin
Rachel Yamin
AJAndrew T. Jones
Andrew T. Jones
HHHans-Heinrich Hoffmann
Hans-Heinrich Hoffmann
ASAlexandra Schäfer
Alexandra Schäfer
KKKevin S. Kao
Kevin S. Kao
SBStylianos Bournazos
Stylianos Bournazos

26 December 2023 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
DKDavid A. Knorr
David A. Knorr
LBLucas Blanchard
Lucas Blanchard
RLRom Leidner
Rom Leidner
SJShawn M. Jensen
Shawn M. Jensen
RMRyan Meng
Ryan Meng
JRJeffrey V. Ravetch
Jeffrey V. Ravetch
Preclinical murine data indicate that fragment crystallizable (Fc)-dependent depletion of intratumoral regulatory T cells (Treg) is a major mechanism of action of anti–CTLA-4. However, the two main antibodies administered to patients (ipilimumab and tremelimumab) do not recapitulate these effects. Here, we investigate the underlying mechanisms responsible for the limited Treg depletion observed with these therapies. Using an immunocompetent murine model humanized for CTLA-4 and Fcγ receptors (FcγR), we show that ipilimumab and tremelimumab exhibit limited Treg depletion in tumors. Immune profiling of the tumor microenvironment (TME) in both humanized mice and humans revealed high expression of the inhibitory Fc receptor, FcγRIIB, which limits antibody-dependent cellular cytotoxicity/phagocytosis. Blocking FcγRIIB in humanized mice rescued the Treg-depleting capacity and antitumor activity of ipilimumab. Furthermore, Fc engineering of antibodies targeting Treg-associated targets (CTLA-4 or CCR8) to minimize FcγRIIB binding significantly enhanced Treg depletion, resulting in increased antitumor activity across various tumor models. Our results define the inhibitory FcγRIIB as an immune checkpoint limiting antibody-mediated Treg depletion in the TME, and demonstrate Fc engineering as an effective strategy to overcome this limitation and improve the efficacy of Treg-targeting antibodies.

6 November 2025 in Science
Verified
Journal Article
Closed access
AJAndrew T. Jones
Andrew T. Jones
AMAlessandra E. Marino
Alessandra E. Marino
TMTetyana Martynyuk
Tetyana Martynyuk
SBStylianos Bournazos
Stylianos Bournazos
JRJeffrey V. Ravetch
Jeffrey V. Ravetch
Intravenous immunoglobulin (IVIG) administered at high doses is used to treat a wide array of autoimmune diseases. Studies in murine models have identified that the anti-inflammatory activity of IVIG is dependent on sialylation of the N-linked glycan on the CH2 domain of immunoglobulin G (IgG), the type I IgG inhibitory Fc receptor FcγRIIB, and the type II Fc receptor dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN). We hypothesized that DC-SIGN, a C-type lectin, may directly interact with glycans on FcγRIIB, augmenting its ability to bind sialylated IgG. We found that Fc-engineering sialylated IgG1 to enhance its affinity for FcγRIIB resulted in a molecule that was more potent than IVIG in reducing the inflammatory sequelae of antibody or T cell–mediated autoimmune diseases, providing the basis for a class of potent anti-inflammatory therapeutics.

22 July 2022 in Science Immunology
Verified
Journal Article
Closed access
ASAnusmita Sahoo
Anusmita Sahoo
AJAndrew T. Jones
Andrew T. Jones
NCNarayanaiah Cheedarla
Narayanaiah Cheedarla
SGSailaja Gangadhara
Sailaja Gangadhara
VRVicky Roy
Vicky Roy
RARama Rao Amara
Rama Rao Amara
The rising global HIV-1 burden urgently requires vaccines capable of providing heterologous protection. Here, we developed a clade C HIV-1 vaccine consisting of priming with modified vaccinia Ankara (MVA) and boosting with cyclically permuted trimeric gp120 (CycP-gp120) protein, delivered either orally using a needle-free injector or through parenteral injection. We tested protective efficacy of the vaccine against intrarectal challenges with a pathogenic heterologous clade C SHIV infection in rhesus macaques. Both routes of vaccination induced a strong envelope-specific IgG in serum and rectal secretions directed against V1V2 scaffolds from a global panel of viruses with polyfunctional activities. Envelope-specific IgG showed lower fucosylation compared with total IgG at baseline, and most of the vaccine-induced proliferating blood CD4 + T cells did not express CCR5 and α4β7, markers associated with HIV target cells. After SHIV challenge, both routes of vaccination conferred significant and equivalent protection, with 40% of animals remaining uninfected at the end of six weekly repeated challenges with an estimated efficacy of 68% per exposure. Induction of envelope-specific IgG correlated positively with G1FB glycosylation, and G2S2F glycosylation correlated negatively with protection. Vaccine-induced TNF-α + IFN-γ + CD8 + T cells and TNF-α + CD4 + T cells expressing low levels of CCR5 in the rectum at prechallenge were associated with decreased risk of SHIV acquisition. These results demonstrate that the clade C MVA/CycP-gp120 vaccine provides heterologous protection against a tier2 SHIV rectal challenge by inducing a polyfunctional antibody response with distinct Fc glycosylation profile, as well as cytotoxic CD8 T cell response and CCR5-negative T helper response in the rectum.

11 October 2021 in Chest
Verified
Journal Article
Open access
PDF file
CMChristopher Mccrae
Christopher Mccrae
JCJennifer Cann
Jennifer Cann
WZWeiguang Zhao
Weiguang Zhao
DCDavid Chain
David Chain
KDKarma Dacosta
Karma Dacosta
AJAndrew Jones
Andrew Jones
TOPIC: Chest Infections

20 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AJAndrew T. Jones
Andrew T. Jones
TMTetyana Martynyuk
Tetyana Martynyuk
AMAlessandra E. Marino
Alessandra E. Marino
SBStylianos Bournazos
Stylianos Bournazos
JRJeffrey V. Ravetch
Jeffrey V. Ravetch
Intravenous immunoglobulin administered at high doses has been used for decades as an effective anti-inflammatory preparation to treat a wide array of autoimmune diseases. Studies in murine models have found this activity to be dependent on 1) sialylation of the N-linked glycan on the CH2 domain of IgG, 2) the type I IgG inhibitory Fc receptor FcγRIIB, and 3) the type II Fc receptor DC-SIGN. Here, we demonstrate that the ectodomain glycan on FcγRIIB interacts with the lectin domain of DC-SIGN to form a cell surface complex, thereby enabling the binding of sialylated IgG1. We have exploited this observation to Fc-engineer sialylated IgG1 to enhance its affinity for FcγRIIB and demonstrate that the resulting molecule is at least 100-fold more potent in reducing the inflammatory sequelae of antibody or T cell mediated autoimmune diseases, providing the basis for a new class of anti-inflammatory therapeutics.